Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Adaptive Optics Retinal Imaging

Food and Drug Administration (FDA) · with University of Maryland, Baltimore · NCT05370287

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 21+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
150
US sites recruiting
1
Study start
January 22, 2018
Record last updated
May 8, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

Being studied: oxygen inhalation; Adaptive optics imaging

Conditions: Glaucoma, Primary Open Angle

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Are 21 years of age or older.
  • Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam).
  • Have the ability to understand and sign an informed consent.
  • Have been diagnosed with POAG (cohort 2).

Exclusion Criteria

  • Are under 21 years of age.
  • Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity).
  • Have visual correction outside of the range +4 diopters (D) to -8 D.
  • Have a history of adverse reaction to mydriatic drops.
  • Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG).
  • Do not meet the criteria for POAG as defined by the American Academy of Ophthalmology Practice Patterns (cohort 2)
  • Have any health conditions that would contraindicate oxygen supplementation, including chronic obstructive pulmonary disease (COPD), emphysema, asthma, or any other obstructive or restrictive lung disease (RBF experiment participants only).
  • Have a dependency on oxygen support or a baseline oxygen saturation \<95% (RBF experiment participants only).
  • Have tested positive for COVID-19 at initial enrollment or have acute or chronic photophobia as a result of contraction.
  • Are working under the direct supervision of Dr. Hammer.

Recruiting US locations

  • Food and Drug Administration

    Silver Spring, MD 20993

    Site contact: Daniel X Hammer, Ph.D. · 301-796-9320 · daniel.hammer@fda.hhs.gov

Study contacts (from the official record)

  • Daniel X Hammer, Ph.D. · 301-796-9320 · daniel.hammer@fda.hhs.gov
  • Zhuolin Liu, Ph.D. · 301-796-7914 · zhuolin.liu@fda.hhs.gov
Adaptive Optics Retinal Imaging (NCT05370287) | Bored Studies